title: de Gramont schedule is a very low toxic and effective regimen in low performance status patients affected by metastatic gastric cancer: preliminary report.
abstract: Treatment of patients affected by metastatic gastric cancer with low performance status (PS) is a very hard choice. It is mandatory to define a very well-tolerated schedule to be employed in these subgroup of patients.
  
  
  METHODS
  From June 1999 to December 2001, 21 patients (pts) affected by metastatic gastric cancer with low performance status (> or = 2 ECOG) were treated with bimonthly "de Gramont" schedule. Treatment was planned to perform 6 courses of chemotherapy for each patient plus other 2-4 if a response had been documented.
  
  
  RESULTS
  A total of 161 courses of de Gramont schedule was administered to the 21 pts enrolled. We observed 8 PD (38%), 8 SD (38%), 5 objective responses (24%--2 MR, 3 PR). Duration of objective responses (OR) was 5 months, 3 months for 3 PRs and 2 and 1 months for two MRs respectively. At time of observation (June 2002) median overall survival (OS) was 14 months, median survival from the starting de Gramont schedule was 8 months. Toxicity was very mild: grade 3 leukopenia in 1 pt, grade 1-2 anemia and piastrinopenia in 3 pts, grade 1-2 nausea vomiting in 5 pts, grade 1 diarrhea in 4 pts, grade 3 mucositis in 2 pts. No other side effect was renowned. PS ameliorated in 12 (57%) pts, even if a major response was not noted.
  
  
  CONCLUSIONS
  de Gramont schedule can be safely and effectively employed in metastatic gastric cancer pts with very low performance status.
authors.affiliation: UO Oncologia, PO Mariano Santo, Azienda Ospedaliera di Cosenza.
authors.forename: Antonio
authors.initials: A
authors.lastname: Rea
authors.forename: Gennaro Gadaleta
authors.initials: GG
authors.lastname: Caldarola
authors.forename: Claudia
authors.initials: C
authors.lastname: Sandomenico
authors.forename: Mauro
authors.initials: M
authors.lastname: Colangelo
authors.forename: Aldo
authors.initials: A
authors.lastname: Filice
authors.forename: Candida Maria
authors.initials: CM
authors.lastname: Mastroianni
authors.forename: Rosalbino
authors.initials: R
authors.lastname: Biamonte
authors.forename: Salvatore
authors.initials: S
authors.lastname: Palazzo
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil